PRESSEMITTEILUNGEN

New York and Stockholm (ots/PRNewswire) – March 2011 Data Confirm Strong Treatment Effect of Chemosaturation

Delcath Systems announced today that James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine, will present updated investigator results from the Phase 3 randomized trial of Delcath’s chemosaturation system with melphalan in patients with hepatic metastases from ocular or cutaneous melanoma.

Dr. Pingpank, a lead principal investigator of the Phase 3 trial, will present the abstract (9304), “Percutaneous Hepatic Perfusion (PHP) vs. Best Alternative Care (BAC) for Patients with Melanoma Liver Metastases – Efficacy Update of the Phase 3 Trial,” in the plenary session today at 11:15am CEST at the European Multidisciplinary Cancer Congress in Stockholm. These updated results include follow-up data from patients through March 2011, an additional 12 months of data maturation from when Dr. Pingpank first presented investigator data from this Phase 3 trial in June 2010, at the American Society of Clinical Oncology’s Annual Meeting.

With respect to the study’s primary endpoint of hepatic progression free survival (“hPFS”), the updated investigator-assessed results showed that patients in the chemosaturation arm demonstrated median hPFS of 8.0 months compared to 1.6 months in the BAC arm, a significant 6.4 month extension of hPFS (hazard ratio 0.35, p

Trackback URL

Alternative Care, American Society Of Clinical Oncology, Cancer Congress, Cutaneous Melanoma, Delcath Systems, Efficacy Results, Free Survival, Hazard Ratio, Liver Metastases, Melanoma, Melphalan, Metastases, Ocular Melanoma, Perfusion, Phase 3, Pittsburgh School, Plenary Session, Prnewswire, School Of Medicine, University Of Pittsburgh School Of Medicine